COMPANY WORKBOOK · NTLA

Intellia Therapeutics, Inc.

Healthcare & Life Sciences · N/A

$12.22+0.66%

32/100

Overall

MARKET CAP1.78B

FORWARD P/E-

PEG RATIO-0.0969

REVENUE GROWTHN/A

OPERATING MARGINN/A

52W RANGE$8.04 – $27.98

INTERACTIVE PRICE CHART

Trend and moving averages

RELATIVE PERFORMANCE

Indexed to 100

LIVE MODEL SCORE

Momentum22

Technicals36

Fundamentals23

Thematic Fit55

Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.

YOUNG BULL THESIS

This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.

MODEL READ

Overall score: 32.3. Last ranked 2026-09-22.

QUARTERLY FUNDAMENTALS

TRAILING P/E-

PRICE / SALES28.78

EV / EBITDA-5.51

BOOK VALUE5.2

GROSS MARGINN/A

PROFIT MARGIN0.0%

RETURN ON EQUITY-55.4%

FREE CASH FLOWN/A

COMPANY SNAPSHOT

Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.

PRIMARY SOURCES